67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis
View abstract on PubMed
Summary
This summary is machine-generated.The 67-kDa laminin receptor (67LR) acts as a cancer-specific death receptor. Inhibiting PDE5 enhances cancer cell death induced by EGCG, offering a potential new cancer therapy.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- The 67-kDa laminin receptor (67LR) is overexpressed in various cancers and promotes tumor growth, metastasis, and chemoresistance.
- 67LR's role in cancer progression and its potential as a therapeutic target are areas of active research.
Purpose Of The Study
- To investigate the role of 67LR as a cancer-specific death receptor.
- To elucidate the signaling pathway involved in 67LR-mediated cancer cell death.
- To evaluate the therapeutic potential of targeting this pathway in cancer treatment.
Main Methods
- Investigated 67LR-mediated cell death pathways using cancer cell lines.
- Examined the role of cGMP, PKCδ/acid sphingomyelinase (ASM) pathway, and phosphodiesterase 5 (PDE5).
- Utilized the green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) as a 67LR ligand and vardenafil (a PDE5 inhibitor) in vitro and in a mouse xenograft model.
Main Results
- 67LR functions as a cancer-specific death receptor, initiating cell death via the cGMP-activated PKCδ/ASM pathway.
- Upregulation of cGMP is crucial for 67LR-dependent cell death induced by EGCG.
- Abnormal PDE5 expression in cancers attenuates 67LR-mediated cell death; vardenafil potentiated EGCG-induced apoptosis and prolonged survival in mice without harming normal cells.
Conclusions
- 67LR-mediated cell death is a novel cancer-specific pathway.
- Targeting PDE5 with inhibitors like vardenafil can enhance cancer-specific apoptosis induced by EGCG.
- PDE5 inhibitors represent a promising strategy to elevate cGMP levels for effective cancer treatment.